Tuesday, 25 June 2019

Aptevo Therapeutics Launches New 3000 IU IXINITY Assay Offering Enhanced User Experience and Improved Convenience for Hemophilia B Patients - Nasdaq

Aptevo Therapeutics Launches New 3000 IU IXINITY Assay Offering Enhanced User Experience and Improved Convenience for Hemophilia B Patients  Nasdaq

Expands Options for Patients with Potential for Reduced Reconstitution Time and Infusion Volume. SEATTLE, June 25, 2019-- Aptevo Therapeutics Inc.,.

Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)